Celestone Soluspan

  • Corticosteroid-responsive disorders

Celestone Soluspan Generic Name & Formulations

General Description

Betamethasone sodium phosphate 3mg/mL, betamethasone acetate 3mg/mL; susp for IM, intra-articular or intralesional inj; contains benzalkonium chloride.

Pharmacological Class


How Supplied

Multi-dose vial (5mL)—1


Celestone Soluspan Indications


Steroid-responsive disorders when oral therapy not feasible.

Celestone Soluspan Dosage and Administration


See full labeling. Individualize. Titrate to lowest effective dose. Usual range: 0.25–9mg/day.


See full labeling. Individualize. Titrate to lowest effective dose. Initially 0.02–0.3mg/kg/day in 3 or 4 divided doses.

Celestone Soluspan Contraindications


IM inj with idiopathic thrombocytopenic purpura.

Celestone Soluspan Boxed Warnings

Not Applicable

Celestone Soluspan Warnings/Precautions


Avoid IV administration. Not for treating traumatic brain injury or optic neuritis. Not for epidural use; serious neurologic events may occur. Concomitant systemic fungal infections, active ocular herpes simplex, cerebral malaria, live vaccines, previously injected joint: not recommended. Latent or active amebiasis. Strongyloides infection. Tuberculosis. If exposed to chickenpox or measles, consider prophylactic immunoglobulin therapy; consider antiviral treatment if chickenpox develops. CHF. Recent MI. Hypertension. Fluid retention. Renal insufficiency. Peptic ulcers. Diverticulitis. Intestinal anastomoses. Ulcerative colitis. Cirrhosis. Unstable or infected joints; avoid. Postmenopausal women (osteoporosis risk). Supplement with additional steroids in physiologic stress. Emotional instability. Psychotic tendencies. Myasthenia gravis. Avoid abrupt cessation. Monitor BP, thyroid, weight, growth, fluid, electrolyte balance and intraocular pressure (w. therapy >6weeks). Pregnancy. Nursing mothers.

Celestone Soluspan Pharmacokinetics

See Literature

Celestone Soluspan Interactions


Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, macrolides, ritonavir, cobicistat-containing products), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine. May potentiate cyclosporine (seizure risk). May antagonize anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin, other NSAIDs. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Concomitant neuromuscular blocking agents; increased risk of myopathy. Withdraw anticholinesterase agents at least 24hrs before initiating corticosteroid therapy. Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. May diminish response to vaccines with long-term use. May suppress reactions to skin tests.

Celestone Soluspan Adverse Reactions

Adverse Reactions

HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, hypokalemia, hypocalcemia, hypernatremia, hypertension, thromboembolism, psychiatric effects, myopathy, osteoporosis, nausea, pancreatitis, peptic ulcer, dermal atrophy, increased sweating, impaired wound healing, increased intracranial pressure, carbohydrate and glucose intolerance, weight gain, inj site reactions, Kaposi's sarcoma, anaphylactoid reactions.

Celestone Soluspan Clinical Trials

See Literature

Celestone Soluspan Note

Not Applicable

Celestone Soluspan Patient Counseling

See Literature